ROS1-dependent cancers—biology, diagnostics and therapeutics
A Drilon, C Jenkins, S Iyer, A Schoenfeld… - Nature reviews Clinical …, 2021 - nature.com
The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown
physiological role in humans. Somatic chromosomal fusions involving ROS1 produce …
physiological role in humans. Somatic chromosomal fusions involving ROS1 produce …
Pediatric low-grade glioma in the era of molecular diagnostics
Low grade gliomas are the most frequent brain tumors in children and encompass a
spectrum of histologic entities which are currently assigned World Health Organisation …
spectrum of histologic entities which are currently assigned World Health Organisation …
Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology
D Sturm, D Capper, F Andreiuolo, M Gessi… - Nature medicine, 2023 - nature.com
The large diversity of central nervous system (CNS) tumor types in children and adolescents
results in disparate patient outcomes and renders accurate diagnosis challenging. In this …
results in disparate patient outcomes and renders accurate diagnosis challenging. In this …
Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas
Pediatric low-grade gliomas (pLGG) are frequently driven by genetic alterations in the RAS-
mitogen-activated protein kinase (RAS/MAPK) pathway yet show unexplained variability in …
mitogen-activated protein kinase (RAS/MAPK) pathway yet show unexplained variability in …
Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes
M Clarke, A Mackay, B Ismer, JC Pickles… - Cancer discovery, 2020 - AACR
Infant high-grade gliomas appear clinically distinct from their counterparts in older children,
indicating that histopathologic grading may not accurately reflect the biology of these tumors …
indicating that histopathologic grading may not accurately reflect the biology of these tumors …
The 2021 WHO classification of tumors of the central nervous system: a summary
The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS),
published in 2021, is the sixth version of the international standard for the classification of …
published in 2021, is the sixth version of the international standard for the classification of …
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
AV Desai, GW Robinson, K Gauvain, EM Basu… - Neuro …, 2022 - academic.oup.com
Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the
treatment of adults and children aged≥ 12 years with NTRK fusion-positive solid tumors and …
treatment of adults and children aged≥ 12 years with NTRK fusion-positive solid tumors and …
Molecular and clinicopathologic features of gliomas harboring NTRK fusions
M Torre, V Vasudevaraja, J Serrano… - Acta Neuropathologica …, 2020 - Springer
Fusions involving neurotrophic tyrosine receptor kinase (NTRK) genes are detected in≤ 2%
of gliomas and can promote gliomagenesis. The remarkable therapeutic efficacy of TRK …
of gliomas and can promote gliomagenesis. The remarkable therapeutic efficacy of TRK …
Major changes in 2021 world health organization classification of central nervous system tumors
The World Health Organization (WHO) published the fifth edition of the WHO Classification
of Tumors of the Central Nervous System (WHO CNS5) in 2021, as an update of the WHO …
of Tumors of the Central Nervous System (WHO CNS5) in 2021, as an update of the WHO …
2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist
The fifth edition of the World Health Organization Classification of Tumours of the Central
Nervous System (WHO CNS5) published in 2021 builds on the 2016 edition and …
Nervous System (WHO CNS5) published in 2021 builds on the 2016 edition and …